Tag:

Copaxone

Latest Headlines

Latest Headlines

It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA

On Thursday, Momenta and Novartis' Sandoz launched their copy of Teva blockbuster Copaxone after a U.S. court nixed the multiple sclerosis drug's patent for the second time. Industry watchers largely expected the move, Bernstein's Ronny Gal wrote in a note to clients. The real question? When Mylan will enter the market with its own copy.

UPDATED: U.S. court nixes Teva's Copaxone patent--again

It's been a long legal road for Copaxone, and one that took yet another turn Thursday as the U.S. Court of Appeals struck down the drug's patent for the second time.

Mapi Pharma closes $10M Series A round after two scuttled IPOs

Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.

Momenta/Sandoz Copaxone generic may be the only one around for a while, exec says

Generics makers have been champing at the bit to get a copy out of Teva's Copaxone, the best-selling multiple sclerosis med that generated $4.2 billion in revenue last year. But according to Momenta CEO Craig Wheeler, his company's version--a joint effort with partner Sandoz, Novartis' generics unit--may be the only knockoff around for a while.

What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds

The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.

Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch?

It's been a long battle since a court upturned Teva's Copaxone patent in July 2013, but a Supreme Court fight, several petitions and a regulatory journey later, Copaxone generics are here.

Teva takes another swing at generic Copaxone with new FDA petition

It's not just that Teva doesn't want the FDA to approve generics of its MS star, Copaxone. It really, really, really does not want the FDA to approve them, and it's filed yet another citizen's petition to the agency with a crop of reasons why it shouldn't.

Teva used kickbacks to boost Copaxone, Azilect scripts, whistleblowers say

After scouring Teva Pharmaceutical for potential marketing and kickback violations for more than a year, the U.S. Justice Department decided not to join up with whistleblowers suing the company. But the two former sales reps are persisting with civil claims that the Israel-based drugmaker used kickbacks, disguised as speaking fees, to persuade doctors to boost prescriptions of its multiple sclerosis drug Copaxone and Parkinson's med Azilect.

Teva wins Copaxone SCOTUS appeal, but its patent battle won't stop there

Teva finally has the Supreme Court Copaxone patent battle victory it's been waiting for--but that doesn't mean its legal journey is over.

Teva continues to whittle down manufacturing network

Teva Pharmaceuticals has cut $650 million in costs this year but needs to more than double that over the next two as it faces generic competition to its workhorse multiple sclerosis drug Copaxone. A big part of that will be to continue revamping its production network, CEO Erez Vigodman says.